Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers
Benveniste, Pierre‐Louis , Létourneau‐Guillon, Laurent , Araújo, David , Fetco, Dumitru , Hori, Masaaki , Kamiya, Kouhei , Messina, Steven, Audoin, Bertrand , Blezek, Daniel, Brisset, Jean‐Christophe , Charlson, Erik, Chen, Michelle , Demortière, Sarah , Edan, Gilles , Filippi, M, Kerbrat, Anne , Kirschke, J, Labauge, Pierre, Liu, Yaou, Mainero, Caterina , Medina, Nilser Laines , Reich, Daniel S. , Shepherd, Timothy M. , Smith, Seth A. , Talbott, Jason, Tauhid, Shahamat , Treaba, Constantina A. , Cohen-Adad, Julien, Fetco, Dumitru , Hori, Masaaki , Audoin, Bertrand , Bakshi, Rohit , Bannier, Elise , Blezek, Daniel , Brisset, Jean-Christophe , Callot, Virginie , Chen, Michelle , Ciccarelli, Olga , Edan, Gilles , Filippi, Massimo , Granberg, Tobias , Granziera, Cristina , Hemond, Christopher C , Keegan, B Mark , Kerbrat, Anne , Kirschke, Jan , Kollind, Shannon H , Lee, Lisa Eunyoung , McGinnis, Julian , Laines Medina, Nilser , Mühlau, Mark , Nair, Govind , O'Grady, Kristin P , Oh, Jiwon , Ouellette, Russell , Reich, Daniel S , Rocca, Maria A , Smith, Seth A , Stawiarz, Leszek , Tam, Roger , Traboulsee, Anthony , Treaba, Constantina Andrada , Valsasina, Paola , Yiannakas, Marios , Cohen-Adad, Julien , Guillon, Laurent Letourneau , Chougar, Lydia , Messina, Steven A. , Tsagkas, Charidimos , Blezek, Daniel J. , Ciccarelli, Olga , Filippi, Massimo , Keegan, B. Mark , Labauge, Pierre , Lee, Lisa Eunyoung , Nair, Govind , O’Grady, Kristin P. , Prat, Alexandre , Rocca, Maria A. , Talbott, Jason F. , Tam, Roger , Lombaert, Hervé

Mayo Clinic

Multiple Sclerosis Journal | April 24, 2026 | Volume: 32 | Issue: 6 | Pages: 598-613

10.1177/13524585261427333 | PMID 42028790 Get It

Background/Objectives: Characterizing spinal cord multiple sclerosis (MS) lesions in MRI is critical for diagnosis, monitoring, and treatment evaluation. However, current automated approaches for lesion detection and segmentation are typically designed for specific MRI contrasts or acquisition sites, limiting their generalizability in real-world clinical settings where imaging protocols vary widely. This work proposes a robust multi-site, multi-contrast segmentation framework for spinal cord lesions. Methods: The segmentation model was trained and evaluated on a large-scale dataset comprising 4428 annotated images from 1849 persons with MS across 23 imaging centers, encompassing six MRI contrasts (T1w, T2w, T2*w, PSIR, STIR, and UNIT1) acquired at 1.5 tesla (T), 3 T, and 7 T. Results: Likert-type assessment performed by neuroradiologist ratings demonstrated superior generalization of the model compared to existing contrast-specific pipelines ( p < 0.01). Additional experiments evaluated robustness across spinal levels, acquisition resolutions, binarization thresholds, and quantitative evaluation on external labeled datasets. Conclusions: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher. Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast
Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM
Crystal, Owen , Farina, Juan Maria M, Scalia, Isabel G. , Ayoub, C A, Park, H B, Arsanjani, R A, Lester, Steven J, Banerjee, Imon, Arsanjani, Reza , Park, Hyung‐Bok , Arsanjani, Reza , Scalia, Isabel G , Park, Hyung Bok , Farina, Juan M. , Etchegoyen, Cecilia Villa , Chollet, Laurève , Kim, Kyung An , Lester, Steven J., Banerjee, Imon

Mayo Clinic

No container title available | April 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.17.26351151 Get It

Abstract Background Accurate assessment of left ventricular outflow tract (LVOT) gradients is critical for hypertrophic cardiomyopathy (HCM) management, yet Doppler-based measurements are technically demanding and require expertise. Objective To develop a multi-view deep learning model capable of classifying LVOT obstruction (> 20mmHg) using routine 2D echocardiographic windows without reliance on Doppler imaging. Methods We trained and externally validated a cross-attention-based video-to-video fusion framework that integrated EchoPrime-derived video representations from three standard transthoracic echocardiographic views to classify LVOT gradients. Results Training was performed on a derivation cohort (N = 1833) from a tertiary care system in the United States, with model performance evaluated on an internal held-out test set (N = 275) and a Korean external validation cohort (N = 46). Single-view baselines showed limited discrimination (external AUROCs 0.47–0.70). Conversely, domain-specific foundational model (EchoPrime) achieved superior single-view performance (AUROCs 0.75–0.80 internal; 0.79–0.83 external), highlighting the importance of echo-specific pretraining and temporal modeling. The proposed multi-view fusion further enhanced predictive performance, with the late fusion model reaching an AUROC of 0.84 on the external cohort with significant population-shift. Conclusions These results suggest LVOT physiology is encoded in routine 2D imaging and can be leveraged for clinically relevant gradient classification without Doppler input- proposed AI-guided strategy demonstrates substantial cost savings compared with the screen-all approach. By integrating complementary spatial-temporal information across multiple views, our approach generalizes robustly across populations and may enable real-time decision support, extend LVOT assessment to portable or resource-limited settings, and complement Doppler-based evaluation for longitudinal HCM management.
Transcatheter Intra‐Arterial Delivery of a Platelet‐Derived Extracellular Vesicle‐Enriched Preparation for Attenuating Skeletal Muscle Ischaemia‐Reperfusion Injury in a Rodent Forelimb Model
Selim, Omar , Sarcon, Aida K. , Behfar, Atta, Zhao, Chunfeng, Moran, Steven L., Selim, Omar A , Sarcon, Aida, Behfar, Atta

Mayo Clinic

Journal of Extracellular Vesicles | April 17, 2026 | Volume: 15 | Issue: 4 | Pages: No page available

10.1002/jev2.70247 | PMID 41995298 Get It

ABSTRACT Extracellular vesicles (EVs) are non‐replicating, lipid membrane‐bound nanoparticles released by most eukaryotic cells into the extracellular space. When derived from platelets, a subset of EVs can exhibit remarkable anti‐inflammatory and antioxidant properties, making them attractive candidates to attenuate sterile inflammatory states such as limb skeletal muscle ischaemia‐reperfusion injury (IRI). Peripheral extremity IRI complicating acute limb revascularisation procedures, replantation of major traumatic amputations and limb allotransplants can trigger a life‐threatening reperfusion syndrome that leads to multi‐organ system failure and death. In this study, we used a platelet‐derived EVs‐enriched preparation as a therapeutic strategy for extremity IRI. To allow for a clinically translatable drug delivery strategy, we established and validated a catheter‐directed regional intra‐arterial limb infusion (RLI) delivery approach that permitted selective and effective targeting of pEVs to limb skeletal muscles and soft tissues in the vascularly isolated rodent extremity simulating pre‐reperfusion preservation and revascularisation conditions of the ischaemic or amputated extremity. In addition to being safe and feasible, we demonstrated robust retention of EVs by skeletal muscles of the operative limb during the early critical phase of reperfusion injury following RLI. We also show that pretreatment of ischaemic skeletal muscles using an pEVs‐enriched formulation just before reestablishing extremity blood flow alleviated metabolic derangements and suppressed the systemic and localised proinflammatory cytokine response associated with skeletal muscle reperfusion and reduced histologic markers of myofibre injury without adverse effects on serum chemistries. This work opens a new perspective to investigate novel approaches for regional delivery of therapeutic pEVs to skeletal muscle to mitigate limb IRI in vivo, and to achieve both in situ and ex vivo targeted delivery of nanocarriers to the isolated limb tissue for other therapeutic applications.
Preoperative (Neoadjuvant) Combined Chemoradiotherapy in the Management of Localized Soft Tissue Sarcoma: A Retrospective Study
Siontis, Brittany L. , Stergiopoulos, Georgios M. , Thangaiah, Judith Jebastin, Ho, Thanh P. , Grotz, Travis E. , Houdek, Matthew T. , Folpe, Andrew L. , Okuno, Scott H. , Jebastin, Judith A S , Ahmed, Safia K. , Grotz, Travis E , Houdek, Matthew T , Okuno, Scott , Siontis, Brittany L , Robinson, Steven I.

Mayo Clinic

Cancers | April 16, 2026 | Volume: 18 | Issue: 8 | Pages: 1260

10.3390/cancers18081260 | PMID 42073583 Get It

Background: Localized soft tissue sarcoma (STS) is primarily treated with surgical resection with or without radiotherapy (RT), while the role of chemotherapy (CT) as a radiosensitizer remains unclear. We report our single-institution experience with combined chemoradiotherapy (CCRT) in treating localized STS. Methods: We conducted a retrospective analysis of patients with localized STS treated at Mayo Clinic with mitomycin, cisplatin, and doxorubicin (MitoAP) concurrently with RT between 1/1/85 and 12/12/19. Results: We identified 179 patients (median age 58 years; median tumor size 9.5 cm), with 83.8% of tumors located in the extremities or trunk. Among them, 77.1% received perioperative CT in addition to CCRT, with 95% of those treated in the neoadjuvant setting. Median RT dose was 50 Gray. The 5-year disease-specific survival (DSS) was 77.9% (95% confidence interval, CI: 70.8–83.4%). The addition of perioperative CT to CCRT was associated with improved DSS compared with CCRT alone (p = 0.01, Hazard Ratio, HR: 0.48, 95% CI: 0.27–0.85). Median post-CCRT tumor viability was 30% and did not differ by CT use (p = 0.39), but varied significantly by histology (p < 0.001). Conclusions: Our institutional protocol utilizing two cycles of MitoAP with RT was well tolerated. DSS in our cohort was similar to historical data using perioperative RT alone, suggesting no clear benefit from CCRT. However, the majority of patients in our cohort were classified as high risk, which may have attenuated a potential survival benefit in the absence of appropriate comparative controls. Furthermore, additional perioperative CT to CCRT was associated with improved DSS and differential histology-specific responses in tumor viability, suggesting that a more aggressive neoadjuvant and perioperative approach may be beneficial in selected patients.
Prognostic value of transaortic flow rate compared with ejection fraction and stroke volume index in low-gradient severe aortic stenosis
Allam, M A, Etchegoyen, Cecilia Villa , Sheashaa, Hesham, Rafie, Nikita , Ibrahim, Ramzi, Mahmoud, Ahmed K, Awad, K, Abdelnabi, Mahmoud, Sell-Dottin, Kristen, Lester, Steven J, Sweeney, John P, Ayoub, Chadi, Lee, K S, Fortuin, David F, Arsanjani, Reza, Villa Etchegoyen, Cecilia , Allam, Mohamed , Alsidawi, Said , Pathangey, Girish , Ibrahim, Ramzi , Farina, Juan M. , Mahmoud, Ahmed , Awad, Kamal , Abdelnabi, Mahmoud , Sell‐Dottin, Kristen , Lester, Steven J., Fortuin, David, Arsanjani, Reza

Mayo Clinic

Heart | April 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: heartjnl-2025-327594

10.1136/heartjnl-2025-327594 | PMID 41980805 Get It

Background In low-gradient severe aortic stenosis (AS), reduced left ventricular ejection fraction (LVEF <50%) is practically used to define low flow and prompt dobutamine stress echocardiography to discern pseudo-severe AS. In patients with preserved LVEF, stroke volume index (SVI) <35 mL/m² is typically used. However, both are volume-based surrogates. Transaortic flow rate (TAFR), calculated as stroke volume divided by left ventricular ejection time, may better reflect true flow. Nonetheless, comparative data between TAFR and established metrics remain limited. We aimed to evaluate the prognostic value of TAFR in symptomatic low-gradient severe AS. Methods We retrospectively identified patients with low-gradient severe AS (AVA ≤1 cm 2 and peak velocity (Vmax) <4 m/s or mean gradient (MG) <40 mm Hg) who underwent transcatheter aortic valve replacement at Mayo Clinic sites (2017–2023). The primary outcome was 1-year all-cause mortality. Survival was assessed using Kaplan-Meier and Cox proportional hazards models. Results Among 475 patients included (mean age 85±8 years; 49% women), 242 (51%) had TAFR <220 mL/s, 165 (35%) had EF <50%, and 221 (47%) had SVI <35 mL/m 2 . Low TAFR was significantly associated with higher 1-year mortality even after stratifying by EF or SVI. In multivariate analysis, TAFR was an independent predictor of mortality (HR 2.38; 95% CI 1.19 to 4.76, p=0.014) after adjusting for reduced LVEF, low SVI, gender, chronic kidney disease and mitral and tricuspid regurgitation. Conclusions In patients with symptomatic low-gradient severe AS, low TAFR, not SVI or LVEF, is independently associated with mortality and may offer more accurate measure of flow state for clinical staging.
Cholangiocyte biology in primary sclerosing cholangitis and other cholangiopathies: pathogenesis, clinical insights, and experimental tools
Jalan-Sakrikar, Nidhi, Anwar, Abid , Ali, Ahmad , Nasser-Ghodsi, Navine, Felzen, Antonia , LaRusso, Nicholas F. , O'Hara, Steven P., Jalan‐Sakrikar, Nidhi , Sakrikar, Nidhi Jalan , Anwar, Abid A, LaRusso, Nicholas F , Ali, Ahmad, Nasser‐Ghodsi, Navine , Huebert, Robert C. , O’Hara, Steven P.

Mayo Clinic

Physiological Reviews | April 13, 2026 | Volume: 106 | Issue: 3 | Pages: 1913-1954

10.1152/physrev.00022.2025 | PMID 41973609 Get It

Cholangiocytes are specialized epithelial cells that line the intrahepatic and extrahepatic biliary tree and play a critical role in bile modification, liver homeostasis, and response to injury. Cholangiocytes exhibit notable heterogeneity and plasticity, and their dysfunction is central to a spectrum of diseases targeting the bile ducts, collectively called cholangiopathies. These disorders include genetic, infectious, immune-mediated, and malignant diseases, with primary sclerosing cholangitis (PSC) representing one of the most complex and enigmatic of these disorders. PSC is a progressive, fibro-inflammatory disease of the bile ducts that is closely linked to inflammatory bowel disease, carries a heightened risk of cancer, and lacks any approved therapies. This review explores the biology of cholangiocytes, including their development, functional plasticity, and roles in secretion, absorption, and cellular signaling. We provide a detailed examination of cholangiopathies, particularly PSC, a complex cholangiopathy characterized by a paradoxical state of cholangiocyte senescence and hyperproliferation. We describe how immune cell dysfunction, the gut microbiome, genetic predispositions, and environmental factors converge to mediate PSC pathogenesis. We revisit the foundational technologies that empowered early discoveries and shaped the field as we know it today. We also explore how newer techniques such as organoid cultures, single-cell transcriptomics, epigenomics, and spatialomics have transformed our modern understanding of biliary pathophysiology. Finally, we provide an overview of existing rodent models of cholangiopathies and discuss their relevance to human disease. PSC remains therapeutically unaddressed, and thus ongoing multidisciplinary efforts are essential to developing targeted interventions. This review serves as a comprehensive resource for researchers and clinicians navigating the rapidly evolving landscape of cholangiocyte-centered liver disease research.
Neonate with Right Hemithorax Opacification
Sittig, Steven E, Sittig, Steven E

Mayo Clinic

Respiratory Care | April 11, 2026 | Volume: 40 | Issue: 3 | Pages: 296-301

10.1177/194336549504000316 Get It

Health system patterns of imaging and fluid biomarker testing in the era of anti‐amyloid therapies
Robb, W Hudson , Kaur, Gurkiran , Huang, Steven K. , Martínez, Felipe Derteano, Nguyen, Ba Thang, Shin, Clifford , Conyers, Christopher T. , Grilli, Christopher, Upjohn, David P., Ortega, V E, Hohman, Timothy J., Keegan, Richard, Cogswell, Petrice M., Graff‐Radford, Jonathan, Johnson, Derek R., Ramanan, Vijay K., Koran, Mary Ellen, Huang, Steven, Nguyen, Ba, Shin, Clifford H, Grilli, Christopher B, Koran, Mary Ellen , Martinez, Felipe, Nguyen, Ba, Yang, Ming , Hohman, Timothy J. , Parent, Ephraim E. , Cogswell, Petrice M. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Koran, Mary Ellen I.

Mayo Clinic

Alzheimer's & Dementia | April 8, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71343 | PMID 41950049 Get It

Abstract INTRODUCTION Anti—amyloid‐β (Aβ) therapies are reshaping Alzheimer's disease (AD) management. Understanding changes in real‐world patterns of diagnostic testing and infusion chair usage is essential for optimizing access to care. METHODS Retrospective analysis of Mayo Clinic enterprise electronic health records (Jan 2019–Mar 2025) assessed trends in AD‐relevant brain imaging, fluid biomarkers, apolipoprotein E (APOE) testing, and lecanemab infusions. Rates of amyloid‐beta (Aβ) positivity by sex and age, APOE genotype frequencies, and lecanemab treatment initiation and discontinuation were evaluated. RESULTS Following national insurance coverage changes, lecanemab infusions grew by 110 infusions per quarter to 605 in Q1 2025. Aβ positron emission tomography scans increased (+22/quarter), cerebrospinal fluid biomarker orders declined (−25/quarter), and plasma p‐tau 217 orders rapidly increased (+238/quarter). Females were more likely to be Aβ positive ( p < 0.006). APOE ‐ε4 homozygotes were less likely to initiate lecanemab (HR = 0.11, p < 0.001). DISCUSSION The adoption of anti‐Aβ therapies coincided with a rapid shift in diagnostic workflows.
Pediatric heart transplantation
Johnson, Jonathan N., Kindel, Steven J. , Ameduri, Rebecca , Johnson, Jonathan N.

Mayo Clinic

Current Opinion in Organ Transplantation | April 4, 2026 | Volume: 31 | Issue: 3 | Pages: 167-171

10.1097/mot.0000000000001289 | PMID 41934116 Get It

Purpose of review To summarize important papers published in the pediatric heart transplantation in the last year. Recent findings While advances have been made for pediatric patients who need heart transplantation, considerable challenges remain. Donor availability remains a key challenge, and work to both increase the number of donors and the quality of donor organs is ongoing. The field of pediatric heart transplantation benefits from registries such as the Pediatric Heart Transplant Society (PHTS) and learning networks such as the Advanced Cardiac Therapies Improving Outcomes Network (ACTION), allowing for multisite collaboration to optimize survival both before and after transplant, and to share learning about complex cases. Psychosocial evaluations of potential recipients and families can be challenging, and a consensus framework is now available for these evaluations, to provide appropriate oversight and management of a scarce resource. Looking ahead, heart transplant specialists are anticipating advances in xenotransplantation, which has the potential to revolutionize current standards of care. Summary Donor availability and organ scarcity are the dominant challenges we face, with many recent impactful papers addressing this issue either directly or indirectly. It will be critical to maintain the forward progress made in addressing these challenges, while readying the field for big changes to come.
Abstract 3140: Characterizing the critical role of enhancer-gene regulation in 5-fluorouracil toxicity and resistance
Krause, Hannah Marie, Magee, Julia, Hahn, Lauryn Allyn, Swartz, Ryan Jonathan, Bembenek, Brianna M. , Jiang, Lulu, Offer, Steven M. , Offer, Steven M , Bouchonville, Kelly J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3140-3140

10.1158/1538-7445.am2026-3140 Get It

Abstract 5-Fluorouracil (5FU)-based chemotherapy remains a front-line treatment for most patients with colorectal cancer. However, approximately 30% of patients who receive 5FU experience severe, life-threatening toxicity. Dihydropyrimidine dehydrogenase (DPD, DPYD gene) mediates the rate determining step in 5FU catabolism. Deleterious genetic variations in DPYD have been associated with elevated concentrations of circulating 5FU and significantly increased risk for 5FU toxicity. Five deleterious variants in DPYD have been identified as clinical biomarkers of toxicity and have led to prospective genotyping and differential dosing recommendations for carriers of these variants, as noted on recent updates to the FDA label for the 5-FU prodrug capecitabine. Our previous studies also established the importance of epigenetic control of DPD expression. In this study, we used existing epigenetic repositories to identify candidate enhancer elements for DPYD. We selected 20 novel high-priority putative enhancers for further study using a combination of reporter assays and CRISPRi applied across multiple cell models. Further studies will investigate means to target these regulatory mechanisms as a means to increase localized efficacy of 5-FU-based therapies in colorectal cancer. Citation Format: Hannah Marie Krause, Julia Magee, Kelly Bouchonville, Lauryn Allyn Hahn, Ryan Jonathan Swartz, Brianna Bembenek, Lulu Jiang, Steven M. Offer. Characterizing the critical role of enhancer-gene regulation in 5-fluorouracil toxicity and resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3140.